Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma

被引:11
|
作者
Laukhtina, Ekaterina [1 ,2 ]
Pradere, Benjamin [1 ,3 ]
D'Andrea, David [1 ]
Rosiello, Giuseppe [4 ,5 ,6 ]
Luzzago, Stefano [4 ,7 ]
Pecoraro, Angela [4 ,8 ]
Palumbo, Carlotta [4 ,9 ,10 ]
Knipper, Sophie [4 ,11 ]
Karakiewicz, Pierre, I [4 ]
Margulis, Vitaly [12 ]
Quhal, Fahad [1 ,13 ]
Sari Motlagh, Reza [1 ]
Mostafaei, Hadi [1 ,14 ]
Mori, Keiichiro [1 ,15 ]
Schuettfort, Victor M. [1 ,16 ]
Enikeev, Dmitry [2 ]
Shariat, Shahrokh F. [1 ,2 ,12 ,17 ,18 ,19 ,20 ,21 ]
机构
[1] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[2] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow, Russia
[3] Univ Hosp Tours, Dept Urol, Tours, France
[4] Univ Montreal Hlth Ctr, Div Urol, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[5] IRCCS San Raffaele Sci Inst, Dept Urol, Milan, Italy
[6] IRCCS San Raffaele Sci Inst, Div Expt Oncol, Urol Res Inst URI, Milan, Italy
[7] IRCCS, Dept Urol, European Inst Oncol, Milan, Italy
[8] Univ Turin, San Luigi Gonzaga Hosp, Dept Urol, Turin, Italy
[9] ASST Spedali Civili Brescia, Dept Med & Surg Specialties, Urol Unit, Brescia, Italy
[10] Univ Brescia, Radiol Sci & Publ Hlth, Brescia, Italy
[11] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[12] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[13] King Fahad Specialist Hosp, Dept Urol, Dammam, Saudi Arabia
[14] Tabriz Univ Med Sci, Res Ctr Evidence Based Med, Tabriz, Iran
[15] Jikei Univ, Dept Urol, Sch Med, Tokyo, Japan
[16] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[17] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[18] Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic
[19] Karl Landsteiner Inst Urol & Androl, Vienna, Austria
[20] Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Div Urol, Amman, Jordan
[21] European Assoc Urol Res Fdn, Arnhem, Netherlands
来源
MINERVA UROLOGY AND NEPHROLOGY | 2022年 / 74卷 / 03期
关键词
Renal cell carcinoma; Neoplasm metastasis; Cytoreduction surgical procedures; Nephrectomy; Survival; Mortality; LYMPHOCYTE RATIO; SURVIVAL; MODEL;
D O I
10.23736/S2724-6051.21.04023-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Identifying those of patients with metastatic renal cell carcinoma (mRCC) who are most likely to benefit from cytoreductive nephrectomy (CN) is challenging. We tested the association between preoperative value of Systemic Immune-Inflammation Index (SII) and overall survival (OS) as well as cancer-specific survival (CSS) in mRCC patients treated with CN. METHODS: mRCC patients treated with CN at different institutions were included. After assessing for the optimal pretreatment SII cut-off value, we found 710 to have the maximum Youden Index value. The overall population was therefore divided into two SII groups using this cut-off (low, <710 vs. high, >= 710). Univariable and multivariable Cox regression analyses tested the association SII and OS as well as CSS. The discrimination of the model was evaluated with the Harrel's Concordance Index (C-Index). The clinical value of the SII was evaluated with decision curve analysis (DCA). RESULTS: Among 613 mRCC patients, 298 (49%) patients had a SII>710. Median follow-up was 31 (IQR 16-58) months. On univariable analysis, high preoperative serum SII was significantly associated with worse OS (HR: 1.28, 95% CI: 1.07-1.54, P=0.01) and CSS (HR: 1.29, 95% CI: 1.08-1.55, P=0.01). On multivariable analysis, which adjusted for the effect of established clinicopathologic features, SII >= 710 was associated with OS (HR: 1.25, 95% CI: 1.04-1.50, P=0.02) and CSS (HR: 1.26, 95% CI: 1.05-1.52, P=0.01). The addition of SII only slightly improved the discrimination of a base model that included established clinicopathologic features (C-index: 0.637 vs. 0.629). On DCA, the inclusion of SII did not improve the net-benefit of the prognostic model. On multivariable analyses, SII >= 710 remained independently associated with the worse OS and CSS in IMDC intermediate risk group (both: HR: 1.31, 95% CI: 1.02-1.67, P=0.03). In the subgroup analyses based on the BMI, among patients with BMI 25, SII was significantly associated with OS (HR: 1.29., 95% CI: 1.04-1.61, P=0.02) and CSS (HR: 1.31, 95% CI: 1.05-1.63, P=0.02). CONCLUSIONS. We found an independent association of high SII prior to CN with unfavorable clinical outcomes, particularly in patients with intermediate risk mRCC and patients with increased BMI. Despite these results, it does not seem to add any prognostic or clinical benefit beyond that obtained by currently available clinicopathologic characteristics as sole worker.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 50 条
  • [41] Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma
    Terasaki, Fumihiro
    Sugiura, Teiichi
    Okamura, Yukiyasu
    Ito, Takaaki
    Yamamoto, Yusuke
    Ashida, Ryo
    Ohgi, Katsuhisa
    Uesaka, Katsuhiko
    SURGERY TODAY, 2021, 51 (10) : 1602 - 1609
  • [42] A Preoperative Prognostic Model for Patients Treated with Nephrectomy for Renal Cell Carcinoma
    Karakiewicz, Pierre I.
    Suardi, Nazareno
    Capitanio, Umberto
    Jeldres, Claudio
    Ficarra, Vincenzo
    Cindolo, Luca
    de la Taille, Alexandre
    Tostain, Jacques
    Mulders, Peter F. A.
    Bensalah, Karim
    Artibani, Walter
    Salomon, Laurent
    Zigeuner, Richard
    Valeri, Antoine
    Descotes, Jean-Luc
    Rambeaud, Jean-Jacques
    Mejean, Arnaud
    Montorsi, Francesco
    Bertini, Roberto
    Patard, Jean-Jacques
    EUROPEAN UROLOGY, 2009, 55 (02) : 287 - 295
  • [43] Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: a meta-analysis
    Zeng, Zesheng
    Xu, Shengen
    Wang, Dingting
    Qin, Gang
    SYSTEMATIC REVIEWS, 2022, 11 (01)
  • [44] Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma
    Laukhtina, Ekaterina
    Pradere, Benjamin
    Andrea, David D.
    Rosiello, Giuseppe
    Luzzago, Stefano
    Pecoraro, Angela
    Palumbo, Carlotta
    Knipper, Sophie
    Karakiewicz, Pierre, I
    Margulis, Vitaly
    Quhal, Fahad
    Motlagh, Reza Sari
    Mostafaei, Hadi
    Mori, Keiichiro
    Kimura, Shoji
    Enikeev, Dmitry
    Shariat, Shahrokh F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (12) : 936.e7 - 936.e14
  • [45] The prognostic role of preoperative systemic immune-inflammation index and albumin/globulin ratio in patients with newly diagnosed high-grade glioma
    Liang, Ruofei
    Li, Junhong
    Tang, Xiaoping
    Liu, Yanhui
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2019, 184
  • [46] Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy
    Kim, Sung Han
    Kim, Jung Kwon
    Park, Boram
    Joo, Jungnam
    Joung, Jae Young
    Seo, Ho Kyung
    Lee, Kang Hyun
    Chung, Jinsoo
    ONCOTARGET, 2017, 8 (30) : 49615 - 49624
  • [47] Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach
    Wing K. Liu
    J. M. Lam
    T. Butters
    M. Grant
    F. Jackson-Spence
    A. Bex
    T. Powles
    B. Szabados
    World Journal of Urology, 2020, 38 : 3199 - 3205
  • [48] Prognostic value of preoperative microscopic hematuria in patients with non-metastatic renal cell carcinoma who underwent nephrectomy
    Tang, Yaxiong
    Shao, Yanxiang
    Hu, Xu
    Ren, Shangqing
    Li, Xiang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (15) : 13545 - 13552
  • [49] Utilization of Partial Cytoreductive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma
    Hauser, Nicholas
    Giakas, Julian
    Robinson, Hunter
    Davaro, Facundo
    Hamilton, Zachary
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (19)
  • [50] Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach
    Liu, Wing K.
    Lam, J. M.
    Butters, T.
    Grant, M.
    Jackson-Spence, F.
    Bex, A.
    Powles, T.
    Szabados, B.
    WORLD JOURNAL OF UROLOGY, 2020, 38 (12) : 3199 - 3205